Q2 2009 Investor Conference Call

Interim report for the second quarter of 2009:

Bayer robust in a difficult environment

HealthCare strong - further growth at CropScience - MaterialScience stabilized / Group sales EUR 8,009 million (minus 5.9 percent) / EBITDA before special items EUR 1,765 million (minus 6.9 percent) / EBIT before special items EUR 1,101 million (minus 11.8 percent) / Group net income EUR 532 million (minus 7.3 percent) / Net cash flow EUR 1,399 million (plus 57.4 percent) / Earnings targets for full year 2009 confirmed more